An Overview on Tumor Treating Fields (Ttfields) Technology As a New Potential Subsidiary Biophysical Treatment for Covid-19 Publisher Pubmed



Farmani AR^{1, 2, 3} ; Mahdavinezhad F⁴ ; Scagnolari C⁵ ; Kouhestani M¹ ; Mohammadi S⁶ ; Ai J¹ ; Shoormeij MH⁷ ; Rezaei N^{8, 9, 10}
Source: Drug Delivery and Translational Research Published:2022

Abstract

COVID-19 pandemic situation has affected millions of people with tens of thousands of deaths worldwide. Despite all efforts for finding drugs or vaccines, the key role for the survival of patients is still related to the immune system. Therefore, improving the efficacy and the functionality of the immune system of COVID-19 patients is very crucial. The potential new, non-invasive, FDA-approved biophysical technology that could be considered in this regard is tumor treating fields (TTFields) based on an alternating electric field has great biological effects. TTFields have significant effects in improving the functionality of dendritic cell, and cytotoxic T-cells, and these cells have a major role in defense against viral infection. Hence, applying TTFields could help COVID-19 patients against infection. Additionally, TTFields can reduce viral genomic replication, by reducing the expressions of some of the vital members of DNA replication complex genes from the minichromosome maintenance family (MCMs). These genes not only are involved in DNA replication but it has also been proven that they have a crucial role in viral replication. Also, TTFields suppress the formation of the network of tunneling nanotubes (TNTs) which is knows as filamentous (F)-actin-rich tubular structures. TNTs have a critical role in promoting the spread of viruses through improving viral entry and acting as a protective agent for viral components from immune cells and even pharmaceuticals. Moreover, TTFields enhance autophagy which leads to apoptosis of virally infected cells. Thus, it can be speculated that using TTFields may prove to be a promising approach as a subsidiary treatment of COVID-19. Graphical abstract: [Figure not available: see fulltext.] © 2021, Controlled Release Society.